angiopathy

(redirected from Amyloid angiopathy)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

angiopathy

[‚an·je′äp·ə·thē]
(medicine)
Any disease of the vascular system.
References in periodicals archive ?
MR spectroscopy in the diagnosis of cerebral amyloid angiopathy presenting as a brain tumor.
Microbleed assessment on T2 *-weighted MRI may serve as a possible marker of both cerebral amyloid angiopathy and hypertensive vasculopathy progression," Dr.
As they observed the mice, they found that the levels of amyloid-beta proteins, which are key markers of Alzheimer's progression in the brain, were reduced by nearly two-thirds (62%), and cerebral amyloid angiopathy (CAA, another marker of the disease in which the amyloid proteins harden the brain's blood vessel walls) was improved by 86 percent.
2]-weighted MRI techniques are improving the ability to detect microbleeds, which are clear markers of hypertensive vasculopathy, cerebral amyloid angiopathy, and other underlying small vessel disease.
Greenberg, a neurologist with the Hemorrhagic Stroke Research Program at Massachusetts General Hospital and Harvard Medical School, Boston, noted that advances in detection are coming at a time when the incidence of hypertensive vasculopathy and cerebral amyloid angiopathy are expected to rise as the Baby Boom generation continues to age.
Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, has been the subject of a completed Phase III clinical trial in North America and is currently being studied in a Phase III clinical trial in Europe, while tramiprosate (CEREBRIL(TM)), for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy, has been studied in a completed Phase IIa clinical trial.
PORTO, PORTUGAL -- Cerebral amyloid angiopathy appears to disproportionately affect the occipital region, according to findings presented at the Fourth International Congress on Vascular Dementia.
Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, has completed a Phase III clinical trial in North America and is currently in a Phase III clinical trial in Europe, while tramiprosate (CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.